Predicting Inflammatory Skin Disease Response to IL-23 Blockade

a study on Psoriasis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Raymond Cho, MD, PhD
Photo of Raymond Cho
Raymond Cho

Description

Summary

This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

Details

This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.

Keywords

Psoriasis Vulgaris Psoriasis Skin Diseases Tildrakizumab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female ≥18 years of age at clinic visit.
  • Documentation of moderate-severe psoriasis or atypical psoriasis.
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

You CAN'T join if...

  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Tuberculosis, active serious infection, active systemic malignancy,
  • Received a systemic medication for psoriasis within 3 months of study screening

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Raymond Cho, MD, PhD
    Dr. Cho investigates the molecular basis of skin disease. He currently develops single-cell molecular fingerprints of unusual skin diseases to identify effective immunomodulatory therapies, in collaboration with the laboratory of Dr. Jeffrey Cheng.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04541329
Phase
Phase 4
Study Type
Interventional
Last Updated
Contact us about this trial